ALSO NOTED: Japan to get Roche's Tarceva next week; Barr sues two generics makers over Seasonale;

> Roche's Japanese unit Chugai Pharmaceutical is preparing to launch the lung-cancer drug Tarceva, approved in Japan in October for treatment of the non-small cell form of the disease. Report

> Barr Pharmaceuticals sued Watson Pharmaceuticals and Sandoz for infringing the patent on Seasonale, a birth control product made by Barr's Duramed unit. Report

> The FDA gave its blessing to Kuvan, a BioMarin Pharmaceutical drug designed to treat the genetic disorder phenylketonuria. Report

> Isis Pharmaceuticals promoted B. Lynne Parshall to chief operating officer; she'll also retain her position as CFO and director. Release

> Forest Laboratories announced that several companies are seeking approval to sell copycat forms of its Alzheimer's drug Namenda. Report

> GlaxoSmithKline is sinking $100 million into a neuroscience research center in China that will play a pivotal role in its ongoing drug discovery work. Report

And Finally... For protection, HIV and aggressive cancer cells cloak themselves in carbo-clothing worn by human sperm. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.